ZYME stock forecast
Our latest prediction for Zymeworks, Inc.'s stock price was made on the Nov. 6, 2018 when the stock price was at 14.08$.
In the short term (2weeks), ZYME's stock price should outperform the market by 0.53%. During that period the price should oscillate between -7.71% and +8.07%.
In the medium term (3months), ZYME's stock price should outperform the market by 1.75%. During that period the price should oscillate between -16.58% and +24.32%.Get email alerts
Create a solid portfolio with ZYME
About Zymeworks, Inc.
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
At the moment the company generates 30M USD in revenues.
On its last earning announcement, the company reported a loss of -3.83$ per share.
The book value per share is 5.83$
Three months stock forecastNov. 6, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|